Memphasys Limited confirms uninterrupted operations across the Middle East and North Africa, securing new orders and advancing regulatory approvals despite ongoing regional tensions.
- Uninterrupted commercial operations in MENA despite regional conflict
- Ongoing clinical use of Felix™ System at Qatar’s Hamad Medical Corporation
- New orders secured from UAE and Iraq customers
- Regulatory progress and reseller partnership advancing in Egypt and Turkey
- Robust supply chain and diversified regional strategy underpin growth
Steady Operations Amid Regional Uncertainty
Memphasys Limited (ASX:MEM), an Australian reproductive biotechnology company, has reported that its commercial activities across the Middle East and North Africa (MENA) region remain uninterrupted despite ongoing geopolitical tensions. The company’s flagship product, the Felix™ System, continues to be used routinely in assisted reproductive technology (ART) procedures, notably at Qatar’s Hamad Medical Corporation (HMC), a key institutional customer.
This resilience is notable given the complex environment in which Memphasys operates. The company’s distribution partner, International Technical Legacy (ITL), has maintained a flexible and reliable supply chain, ensuring that logistics and deliveries proceed without delay across all contracted territories.
Expanding Footprint with New Market Entries
Beyond Qatar, Memphasys is actively expanding its commercial footprint. New orders have been secured from clinics in the United Arab Emirates and Iraq, signalling sustained demand and successful direct engagement strategies. These initial orders are part of a broader plan to build recurring cartridge revenue through progressive clinic onboarding.
In addition, the company is advancing regulatory approvals and market entry strategies in Egypt and Turkey. Egypt, identified as one of the largest and fastest-growing IVF markets in the region, now has a confirmed reseller partnership with ITL. Initial trial orders are expected next quarter, following positive reception at a recent IVF conference in Cairo.
Turkey’s regulatory process is also progressing on schedule, with first commercial orders anticipated soon. Turkey’s established fertility sector and strategic location offer Memphasys an opportunity to extend Felix™ adoption both domestically and into adjacent markets.
Diversified Strategy Mitigates Risk
Memphasys’ commercial approach focuses on generating demand at the clinic level across multiple countries, rather than relying heavily on distributor-led sales in a single market. This diversification reduces exposure to any one country’s geopolitical risks and supports a more resilient revenue profile.
Chair of the Commercialisation Committee, Marjan Mikel, emphasised the strength of this model, noting that ongoing institutional usage, new orders, and regulatory progress collectively demonstrate broad-based traction. The company’s supply chain flexibility further supports its ability to adapt to changing regional conditions.
Outlook and Investor Considerations
Looking ahead, Memphasys remains confident in its MENA rollout and broader international expansion. The company plans to keep shareholders informed on additional commercial orders, regulatory milestones, and clinic adoption growth. While the geopolitical environment remains uncertain, Memphasys currently does not anticipate any material impact on its operations or commercial trajectory.
Bottom Line?
Memphasys’ diversified MENA strategy and robust supply chain position it well for growth despite regional uncertainties.
Questions in the middle?
- How quickly will regulatory approvals in Egypt and Turkey translate into sustained commercial sales?
- What is the potential scale of recurring cartridge revenue from new markets like UAE and Iraq?
- Could escalating geopolitical tensions disrupt supply chains or customer engagement in the near term?